
Health is the foundation of American freedom
To pursue life, liberty, and happiness — not just politically but through our everyday lives — you need health.
If you are unwell, if you're struggling with chronic illness, pain, depression, or the crushing burden of medical debt, your capacity to live freely, to pursue your dreams, becomes more constrained. While health is not listed in the Declaration of Independence as an inalienable right, it is a key enabler of those rights. When people are able to keep themselves, and those they love, healthy, they have the agency to live the lives they choose.
The biotechnology revolution of the past decade is expanding that freedom. We are living through a remarkable era of health breakthroughs, from
Advertisement
CRISPR is being used to treat once-untreatable genetic disorders and recently helped save the life of a
Advertisement
These gains in health are expanding freedom — and our ability to meaningfully pursue our unalienable rights. That health-driven freedom is exactly what is at risk today as the federal government reconsiders its investments in
These breakthroughs — and the thousands of things that happen every day in the American health care system — have no value if people can't access them. A strong health care system makes routine what is extraordinary. Heart bypass surgeries, cataract surgeries, cesarean sections, joint replacements — procedures that were once rare or risky are now commonplace and performed safely every day. Screenings catch diseases early, when they're the most treatable. This kind of health care gives people the ability to shape their lives on their own terms. A hip replacement means that an older man can take walks again with his grandchildren. A heart bypass surgery means a middle-aged woman knows she will live to see her children married or her grandkids born and growing. It means returning to work, raising a family, being there for loved ones, growing older with dignity. That's how life, liberty, and the pursuit of happiness become real and not just the promise of our Founding Fathers.
Advertisement
And these aren't just ideas. There is strong empirical evidence that this is so. When people have access to quality health care,
It's also why we as Americans should understand health as a foundational element of freedom. Because when Americans are healthy, they are more able to live, to choose, to flourish. They are more able to exercise the freedoms our founders envisioned.
On Independence Day, politicians will speak of freedom. True freedom, however, requires not just platitudes but actual policies that improve health through innovation, access, and reduced costs. Funding science research and ensuring universal access to health care are critical to realizing the Declaration's promise of life, liberty, and happiness.
Advertisement

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
21 minutes ago
- The Hill
22 Palestinians killed in Gaza as Israeli forces fire on crowds at food aid sites, medics say
CAIRO (AP) — Israeli forces killed at least 22 people and wounded 20 others, many while attempting to get desperately needed food aid in southern Gaza on Monday, according to witnesses, hospitals, and Gaza's Health Ministry. Nasser Hospital in Khan Younis said it received the bodies of 11 people who were shot while returning from an aid site associated with Israeli and U.S.-backed Gaza Humanitarian Fund in southern Gaza, part of a deadly pattern that has killed more than 500 Palestinians in the chaotic and controversial aid distribution program over the past month. Ten others were killed at a United Nations aid warehouse in northern Gaza, according to the Health Ministry. The southern Gaza strike happened around 3 kilometers (1.8 miles) from the GHF site in the city of Khan Younis, as Palestinians returned from the site along one of the only accessible routes. Palestinians are often forced to travel long distances to access the GHF hubs in hopes of obtaining aid. Yousef Mahmoud Mokheimar was walking along with dozens others when he saw troops in vehicles and tanks racing toward them. At the beginning they fired warning shots in air, before firing at the crowds, he said. 'They fired at us indiscriminately,' he said, adding that he was shot in his leg, and a man was also shot while attempting to rescue him. He said he saw troops detaining six people, including three children, and it wasn't clear what happened to them. 'We don't know whether they are still alive,' he said. Monzer Hisham Ismail, another witness, said troops attacked the crowds while returning from the GHF hub in eastern Khan Younis. 'We were returning from the American aid hub … we were targeted by (the Israeli) artillery,' he said. Nasser Hospital said another person was killed near a GHF hub in the southern city of Rafah. The Israeli military said it was reviewing information about the attacks. In the past, the military has said it fires warning shots at people who move suspiciously or get too close to troops, including while collecting aid. Israel wants the GHF to replace a system coordinated by the United Nations and international aid groups. Along with the United States, Israel has accused the militant Hamas group of stealing aid and using it to prop up its rule in the enclave. The U.N. denies there is systematic diversion of aid. The Israeli military said it had recently taken steps to improve organization in the area, including the installation of new fencing, signage and the opening of additional routes to access aid. Israel says it only targets militants and blames civilian deaths on Hamas, accusing the militants of hiding among civilians because they operate in populated areas. In northern Gaza, at least 10 Palestinians were killed in an Israeli strike on an aid warehouse in Gaza City, according to the Health Ministry's ambulance and emergency service. It wasn't immediately clear whether there was aid at the warehouse. The strike in Gaza City came as the military intensified its bombardment campaign across the city and the nearby Jabaliya refugee camp. On Sunday and Monday, Israel issued widespread evacuation orders for large swaths of northern Gaza. Palestinians reported massive bombing overnight into Monday morning, describing the fresh attacks as a 'scorched earth' campaign that targeted mostly empty buildings and civilian infrastructure above the ground. 'They destroy whatever left standing … the sound of bombing hasn't stopped,' said Mohamed Mahdy, a Gaza City resident who fled his damaged house Monday morning. Fares Awad, head of the Health Ministry's emergency and ambulance services in northern Gaza, said that most of Gaza City and Jabaliya have become inaccessible and ambulances were unable to respond to distress calls from people trapped in the rubble. The Israeli military said it had taken multiple steps to notify civilians of operations to target Hamas' military command and control centers in northern Gaza. ___ Lidman reported from Tel Aviv, Israel. ___ Follow the AP's war coverage at


Miami Herald
23 minutes ago
- Miami Herald
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%. "Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines." In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1] According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3] P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest. Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris RidleyHead of Global Media Relations+1 Investors: Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc.


Axios
25 minutes ago
- Axios
Trump tariffs could dampen July Fourth fireworks for 2026
As Americans prepare to light up the skies this Fourth of July, the fireworks industry is sounding the alarm: without tariff relief, the nation's 250th birthday celebration in 2026 could be in jeopardy. Why it matters: A looming tariff burden on Chinese imports is sparking fears of higher costs, supply shortages and even canceled shows. "If the tariff increases again back up to triple digits — let's say 145% — it will cripple this industry," Julie Heckman, executive director of the American Pyrotechnics Association, told Axios. The big picture: 99% of consumer fireworks and 90% of professional display fireworks used in the U.S. come from China, Heckman said. A 25% to 145% tariff imposed under a trade provision known as Section 301 is adding strain to the supply chain and pricing. China typically halts fireworks production during hot summer months due to safety risks, narrowing the window for U.S. importers to place and receive orders. Zoom in: Bruce Zoldan, CEO of Ohio-based Phantom Fireworks, told Axios that his 100 stores have seen a big surge in recent days. Over the weekend, Phantom also opened 1,600 seasonal stands and tents. "People are starting to buy now," he said, noting sales are almost 30% higher per day than last year. "If you wait until July 1st, 2nd, or 3rd, half the merchandise is sold out and the lines are long." Phantom — the nation's largest consumer-based retail fireworks company, supplying thousands of stores nationwide like Home Depot — received 85% of its inventory prior to tariffs, Zoldan said. "There could be a few minor changes, but for the most part, our prices are stable with the last year," he said. "Now, going into next year that's another story." State of play: Industry leaders say they need an exemption like the one President Trump granted in 2019 to move forward with planning for 2026 and beyond. "Thirty percent is not sustainable — not going into what we think will be the biggest celebration, consumption of fireworks ever on record," Heckman told Axios. "This isn't political for us," Heckman said. "We support the president 100%, and themajority of firework entities and their customers — the folks coming in to celebrate Independence Day — they are his base." The other side: The White House pushed back on the fireworks industry's plea for tariff relief. "Real prosperity and patriotism isn't celebrating the independence of our country with cheap foreign-made firecrackers and trinkets," White House spokesman Kush Desai said in a statement to Axios. "It's having a country with booming Main Streets, a thriving working class, and robust manufacturing." Yes, but: Heckman said moving fireworks production stateside is impossible, especially for 2026. "Even if we brought some manufacturing back to the U.S., it wouldn't be optimal," Heckman said, noting it's highly dangerous, labor-intensive and regulated. "We could never produce the volume the U.S. relies on for celebrating Independence Day." What's next: Heckman said her organization has been advocating on Capitol Hill and has a meeting in late July with the U.S. Trade Representative's office. "Right now, we're at a standstill," Zoldan said of the fireworks industry. "We're getting close to the point where we have to place our orders for next year, and they have to start manufacturing right after Labor Day." Zoldan said any delay past Labor Day for submitting orders means a certain percentage won't be manufactured in time to get to America.